Mantle cell lymphoma is one of the non-Hodgkin lymphomas, i.e. cancers that originate from immune cells. Various drugs are available to treat mantle cell lymphoma. Bortezomib and ibrutinib are two such drugs. These two active substances are currently used individually, i.e. not in combination, to treat mantle cell lymphoma.
The aim of this pase I/II trial SAKK 36/13 is to establish whether bortezomib and ibrutinib can be administered together. In this study, patients who have already received ineffective treatment for mantle cell lymphoma or who subsequently suffered a relapse will be treated with bortezomib and ibrutinib in combination.